195 related articles for article (PubMed ID: 36097178)
21. FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
Weiss A; Adler F; Buhles A; Stamm C; Fairhurst RA; Kiffe M; Sterker D; Centeleghe M; Wartmann M; Kinyamu-Akunda J; Schadt HS; Couttet P; Wolf A; Wang Y; Barzaghi-Rinaudo P; Murakami M; Kauffmann A; Knoepfel T; Buschmann N; Leblanc C; Mah R; Furet P; Blank J; Hofmann F; Sellers WR; Graus Porta D
Mol Cancer Ther; 2019 Dec; 18(12):2194-2206. PubMed ID: 31409633
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast growth factor receptor type 4 as a potential therapeutic target in clear cell renal cell carcinoma.
Narisawa T; Naito S; Ito H; Ichiyanagi O; Sakurai T; Kato T; Tsuchiya N
BMC Cancer; 2023 Feb; 23(1):170. PubMed ID: 36803783
[TBL] [Abstract][Full Text] [Related]
23. FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma.
Sullivan PM; Kumar R; Li W; Hoglund V; Wang L; Zhang Y; Shi M; Beak D; Cheuk A; Jensen MC; Khan J; Dimitrov DS; Orentas RJ
Mol Cancer Ther; 2022 Oct; 21(10):1608-1621. PubMed ID: 35877472
[TBL] [Abstract][Full Text] [Related]
24. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.
Seki M; Nishimura R; Yoshida K; Shimamura T; Shiraishi Y; Sato Y; Kato M; Chiba K; Tanaka H; Hoshino N; Nagae G; Shiozawa Y; Okuno Y; Hosoi H; Tanaka Y; Okita H; Miyachi M; Souzaki R; Taguchi T; Koh K; Hanada R; Kato K; Nomura Y; Akiyama M; Oka A; Igarashi T; Miyano S; Aburatani H; Hayashi Y; Ogawa S; Takita J
Nat Commun; 2015 Jul; 6():7557. PubMed ID: 26138366
[TBL] [Abstract][Full Text] [Related]
25. Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells.
Jiang D; Li J; Li J; Wang M; Han C; Wang X; Zhao C; Ye Y
Int J Oncol; 2017 Nov; 51(5):1611-1620. PubMed ID: 29048661
[TBL] [Abstract][Full Text] [Related]
26. Signaling pathways in Rhabdomyosarcoma invasion and metastasis.
Ramadan F; Fahs A; Ghayad SE; Saab R
Cancer Metastasis Rev; 2020 Mar; 39(1):287-301. PubMed ID: 31989508
[TBL] [Abstract][Full Text] [Related]
27. Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455.
Wu D; Guo M; Philips MA; Qu L; Jiang L; Li J; Chen X; Chen Z; Chen L; Chen Y
PLoS One; 2016; 11(9):e0162491. PubMed ID: 27618313
[TBL] [Abstract][Full Text] [Related]
28. FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer.
Peláez-García A; Barderas R; Torres S; Hernández-Varas P; Teixidó J; Bonilla F; de Herreros AG; Casal JI
PLoS One; 2013; 8(5):e63695. PubMed ID: 23696849
[TBL] [Abstract][Full Text] [Related]
29. Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-
Yang F; Chen X; Song X; Ortega R; Lin X; Deng W; Guo J; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
J Med Chem; 2022 Nov; 65(21):14809-14831. PubMed ID: 36278929
[TBL] [Abstract][Full Text] [Related]
30. Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcoma.
Nakagawa N; Kikuchi K; Yagyu S; Miyachi M; Iehara T; Tajiri T; Sakai T; Hosoi H
Biochem Biophys Res Commun; 2019 May; 512(3):524-530. PubMed ID: 30904164
[TBL] [Abstract][Full Text] [Related]
31. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Gao L; Shay C; Lv F; Wang X; Teng Y
Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
[TBL] [Abstract][Full Text] [Related]
32. Photoactivation approaches reveal a role for Rab11 in FGFR4 recycling and signalling.
Haugsten EM; Brech A; Liestøl K; Norman JC; Wesche J
Traffic; 2014 Jun; 15(6):665-83. PubMed ID: 24589086
[TBL] [Abstract][Full Text] [Related]
33. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
Shern JF; Chen L; Chmielecki J; Wei JS; Patidar R; Rosenberg M; Ambrogio L; Auclair D; Wang J; Song YK; Tolman C; Hurd L; Liao H; Zhang S; Bogen D; Brohl AS; Sindiri S; Catchpoole D; Badgett T; Getz G; Mora J; Anderson JR; Skapek SX; Barr FG; Meyerson M; Hawkins DS; Khan J
Cancer Discov; 2014 Feb; 4(2):216-31. PubMed ID: 24436047
[TBL] [Abstract][Full Text] [Related]
35. Proximity Labeling Reveals Molecular Determinants of FGFR4 Endosomal Transport.
Haugsten EM; Sørensen V; Kunova Bosakova M; de Souza GA; Krejci P; Wiedlocha A; Wesche J
J Proteome Res; 2016 Oct; 15(10):3841-3855. PubMed ID: 27615514
[TBL] [Abstract][Full Text] [Related]
36. FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas.
Milton CI; Selfe J; Aladowicz E; Man SYK; Bernauer C; Missiaglia E; Walters ZS; Gatz SA; Kelsey A; Generali M; Box G; Valenti M; de Haven-Brandon A; Galiwango D; Hayes A; Clarke M; Izquierdo E; Gonzalez De Castro D; Raynaud FI; Kirkin V; Shipley JM
Mol Oncol; 2022 Mar; 16(6):1272-1289. PubMed ID: 34850536
[TBL] [Abstract][Full Text] [Related]
37. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
38. Blocking FGFR4 exerts distinct anti-tumorigenic effects in esophageal squamous cell carcinoma.
Xin Z; Song X; Jiang B; Gongsun X; Song L; Qin Q; Wang Q; Shi M; Liu X
Thorac Cancer; 2018 Dec; 9(12):1687-1698. PubMed ID: 30267473
[TBL] [Abstract][Full Text] [Related]
39. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation.
Nam Y; Shin I; Kim Y; Ryu S; Kim N; Ju E; Sim T
Neoplasia; 2022 Jan; 24(1):34-49. PubMed ID: 34864570
[TBL] [Abstract][Full Text] [Related]
40. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
Yohe ME; Gryder BE; Shern JF; Song YK; Chou HC; Sindiri S; Mendoza A; Patidar R; Zhang X; Guha R; Butcher D; Isanogle KA; Robinson CM; Luo X; Chen JQ; Walton A; Awasthi P; Edmondson EF; Difilippantonio S; Wei JS; Zhao K; Ferrer M; Thomas CJ; Khan J
Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]